On February 28, 2018, the Board of Directors of Kala Pharmaceuticals, Inc. increased the size of the Board from nine to ten directors and, following the recommendation of the Nominating and Corporate Governance Committee, appointed Gregory Perry as a director, effective immediately. Mr. Perry will serve as a Class I director with a term expiring at the 2018 Annual Meeting of Stockholders and thereafter until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. Mr. Perry will serve as Chair of the Audit Committee. Mr. Perry served as Chief Financial and Administrative Officer of Novelion Therapeutics Inc., from November 2016 to December 2017.